Table 1.
Baseline Demographic and Clinical Characteristics of Patients.
| Characteristics | N (%) or median (range) |
|---|---|
| Total | 53 (100%) |
| Age (mean ± SD, years) | 56.9 years (range, 37-75 years) |
| Lower age (≤60 years) | 31 (58.5%) |
| Higher age (>60 years) | 22 (41.5%) |
| Gender | |
| Male | 45 (84.9%) |
| Female | 8 (15.1%) |
| Bodyweight, kg | |
| <60 | 20 (37.7%) |
| ≥60 | 33 (62.3%) |
| ECOG PS | |
| 0 | 34 (64.2%) |
| 1 | 19 (35.8%) |
| AFP (ng/ml) | |
| Low (<400) | 35 (66.0%) |
| High (≥400) | 18 (34.0%) |
| Liver cirrhosis | |
| No | 45 (84.9%) |
| Yes | 8 (15.1%) |
| Child-pugh score | |
| 5 | 19 (35.8%) |
| 6 | 15 (28.3%) |
| 7 | 19 (35.8%) |
| Etiology | |
| HBV | 45 (84.9%) |
| HCV | 5 (9.4%) |
| Alcohol | 3 (5.7%) |
| Vascular invasion | |
| No | 28 (52.8%) |
| Yes | 25 (47.2%) |
| Extrahepatic metastasis | |
| Lung | 10 (18.9%) |
| Lymph node | 21 (39.6%) |
| Bone | 6 (11.3%) |
| Other | 5 (9.4%) |
| BCLC stage | |
| B | 23 (43.4%) |
| C | 30 (56.6%) |
| Prior therapies | |
| Surgery | 9 (17.0%) |
| Ablation | 29 (54.7%) |
| TACE | 33 (62.3%) |
| TKIs | 24 (45.3%) |
| PD-1 inhibitors | |
| Camrelizumab | 25 (47.2%) |
| Sintilimab | 28 (52.8%) |